Search results for : braf - Cancerrxgene - Genomics of Drug Sensitivity in Cancer

Search Results for: braf

Drugs (10)
Genetic Features (1)

Name	Synonyms	Targets	Target Pathway	PubCHEM	Datatset	Sample size	Screening site
AZ628	AZ-628, AZ 628	BRAF	ERK MAPK signaling	11676786	GDSC1	401	MGH
Dabrafenib	GSK2118436, Tafinlar	BRAF	ERK MAPK signaling	44462760	GDSC1	859	SANGER
Dabrafenib	GSK2118436, Tafinlar	BRAF	ERK MAPK signaling	44462760	GDSC2	954	SANGER
HG6-64-1	KIN001-206	BRAF	ERK MAPK signaling	53302361	GDSC1	875	MGH
PLX-4720	PLX4720, PLX 4720	BRAF	ERK MAPK signaling	24180719	GDSC1	930	SANGER
PLX-4720	PLX4720, PLX 4720	BRAF	ERK MAPK signaling	24180719	GDSC1	913	SANGER
PLX-4720	PLX4720, PLX 4720	BRAF	ERK MAPK signaling	24180719	GDSC2	961	SANGER
RAF_9304	SN1034259943	ARAF, BRAF, CRAF	ERK MAPK signaling		GDSC1	918	SANGER
SB590885	SB-590885	BRAF	ERK MAPK signaling	11316960	GDSC1	895	SANGER
SB590885	SB-590885	BRAF	ERK MAPK signaling	11316960	GDSC2	944	SANGER

Feature Name	Feature Type
BRAF_mut	coding variant

The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project at the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.

Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.
Please note: The data files are experimental and academic in nature and are not licensed or certified by any regulatory body. Genome Research Limited provides access to data files on an “as is” basis and excludes all warranties of any kind (express or implied).